{
    "clinical_study": {
        "@rank": "19940", 
        "arm_group": [
            {
                "arm_group_label": "Liposome bupivacaine", 
                "arm_group_type": "Active Comparator", 
                "description": "Single total administration of 266 mg (approximately 88 mg to each of three nerve segments) of 6.6 mL volume each for a total of 20 mL."
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Single total administration of 266 mg (approximately 88 mg to each of three nerve segments) of 6.6 mL volume each for a total of 20 mL"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of the study is to examine the safety and efficacy of liposome bupivacaine for\n      intercostal nerve block in subjects undergoing posterolateral thoracotomy."
        }, 
        "brief_title": "Intercostal Nerve Block With Liposome Bupivacaine in Subjects Undergoing Posterolateral Thoracotomy", 
        "completion_date": {
            "#text": "July 2013", 
            "@type": "Actual"
        }, 
        "condition": [
            "Posterolateral Thoracotomy", 
            "Postoperative Pain"
        ], 
        "condition_browse": {
            "mesh_term": "Pain, Postoperative"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male or female, \u226518 years of age.\n\n          -  Scheduled to undergo a thoracotomy of at least 3 inches (7.6 cm) of intercostal\n             incisional length or requiring insertion of an inter-rib spreader/retractor for a\n             primary thoracic non-infectious indication under general anesthesia.\n\n          -  American Society of Anesthesiologists (ASA) Physical Status 1 - 3.\n\n          -  Able to provide informed consent, adhere to the study visit schedule, and complete\n             all study assessments.\n\n          -  Able to demonstrate sensory function by exhibiting sensitivity to cold in one\n             dermatome area in which study drug will be administered.\n\n        Exclusion Criteria:\n\n          -  Currently pregnant, nursing, or planning to become pregnant during the study or\n             within 1 month after study drug administration.  Female subjects must be surgically\n             sterile, at least 2 years menopausal, or using an acceptable method of birth control.\n              If of childbearing potential, must have a documented negative pregnancy test within\n             24 hours before surgery.\n\n          -  Any planned pleurodesis as part of the surgical procedure.\n\n          -  Use of any of the following medications within the times specified before surgery:\n             long-acting opioid medication, non-steroidal anti-inflammatory drug (NSAID), or\n             aspirin (except for low-dose aspirin used for cardioprotection or\n             acetaminophen/paracetamol) within 3 days and any opioid medication within 24 hours.\n\n          -  Use of selective serotonin reuptake inhibitors (SSRIs), gabapentin, pregabalin\n             (Lyrica\u00ae), or duloxetine (Cymbalta\u00ae) within 3 days of surgery.\n\n          -  Concurrent painful physical condition or concurrent surgery that may require\n             analgesic treatment (such as an NSAID or opioid) in the postsurgical period for pain\n             that is not strictly related to the surgery, and which may confound the postsurgical\n             assessments (e.g., cancer pain, chronic neuropathic pain, concurrent abdominal\n             surgery).\n\n          -  Current use of systemic glucocorticosteroids within 1 month of enrollment.\n\n          -  Body weight < 50 kilograms (110 pounds) or a body mass index \u2265 35 kg/m2.\n\n          -  Contraindication to any of the pain-control agents planned for surgical or\n             postsurgical use (i.e., fentanyl, morphine, hydromorphone, oxycodone, or\n             bupivacaine).\n\n          -  Administration of an investigational drug within 30 days or 5 elimination half-lives\n             of such investigational drug, whichever is longer, prior to study drug\n             administration, or planned administration of another investigational product or\n             procedure during the subject's participation in this study.\n\n          -  Previous participation in a liposome bupivacaine study.\n\n          -  History of, suspected, or known addiction to or abuse of illicit drug(s),\n             prescription medicine(s), or alcohol within the past 2 years.\n\n          -  Uncontrolled anxiety, schizophrenia, or other psychiatric disorder that, in the\n             opinion of the Investigator, could interfere with study assessments or compliance.\n\n          -  Current or historical evidence of any clinically significant disease or condition,\n             especially cardiovascular or neurological conditions that, in the opinion of the\n             Investigator, may increase the risk of surgery or complicate the subject's\n             postsurgical course or interfere with the determination of pain intensity related\n             solely to the surgery.\n\n          -  Significant medical conditions (including widely disseminated metastatic disease) or\n             laboratory results that, in the opinion of the Investigator, indicate an increased\n             vulnerability to study drugs and procedures.\n\n          -  Subjects who are planned to receive Entereg\u00ae (alvimopan).\n\n          -  Subjects who will receive prophylactic antiemetics or planned postsurgical\n             antiemetics given without regard to the subject's emesis needs."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "191", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "February 26, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01802411", 
            "org_study_id": "402-C-322"
        }, 
        "intervention": [
            {
                "arm_group_label": "Liposome bupivacaine", 
                "intervention_name": "Liposome bupivacaine", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Bupivacaine"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "liposome bupivacaine", 
            "posterolateral thoracotomy", 
            "intercostal nerve block", 
            "postoperative pain"
        ], 
        "lastchanged_date": "October 9, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Miami", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33136"
                    }, 
                    "name": "Jackson Memorial Hospital/University of Miami, 1611 NW 12th Avenue (R-C300)"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Shreveport", 
                        "country": "United States", 
                        "state": "Louisiana", 
                        "zip": "71103"
                    }, 
                    "name": "Louisiana State University Health Sciences Center - Shreveport, 1501 Kings Hwy"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Fargo", 
                        "country": "United States", 
                        "state": "North Dakota", 
                        "zip": "58122"
                    }, 
                    "name": "Sanford Heart Center 801 Broadway North"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bellaire", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "77401"
                    }, 
                    "name": "Research Concepts, GP, LLC, 4525 Texas St."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Dallas", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "75390-8879"
                    }, 
                    "name": "UT Southwestern Medical Center, Dept. Cardiovas7726cular & Thoracic Surgery, 5909 Harry Hines Blvd., 9th Fl."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Houston", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "77030"
                    }, 
                    "name": "The Methodist Hospital UANEU25, Department of Cardiovascular Surgery, 6550 Fannin, Suite 1401"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tacoma", 
                        "country": "United States", 
                        "state": "Washington", 
                        "zip": "98405"
                    }, 
                    "name": "MultiCare Health System dba Tacoma General Hospital 315 Martin Luther King Jr Way"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo Controlled Study to Assess the Efficacy and Safety of Intercostal Nerve Block With Liposome Bupivacaine in Subjects Undergoing Posterolateral Thoracotomy", 
        "overall_official": {
            "affiliation": "Pacira Pharmaceuticals, Inc", 
            "last_name": "Erol Onel, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "June 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Area Under the Curve (AUC) of the Numeric Rating Scale (NRS) Scores at Rest for Pain Intensity", 
            "safety_issue": "No", 
            "time_frame": "Through 72 hours"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01802411"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Total postsurgical opioid consumption (mg)", 
                "safety_issue": "No", 
                "time_frame": "Through 72 hours"
            }, 
            {
                "measure": "Time to first opioid use", 
                "safety_issue": "No", 
                "time_frame": "Day 1"
            }
        ], 
        "source": "Pacira Pharmaceuticals, Inc", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pacira Pharmaceuticals, Inc", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}